Clinical Trial Detail

NCT ID NCT03018405
Title A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celyad Oncology SA
Indications

ovary epithelial cancer

colorectal cancer

triple-receptor negative breast cancer

transitional cell carcinoma

multiple myeloma

acute myeloid leukemia

pancreatic cancer

fallopian tube carcinoma

myelodysplastic syndrome

Therapies

NKR-2 cells

Age Groups: adult senior

No variant requirements are available.